Bio CEO & Investor Conference
February 13-14, 2017
The Waldorf Astoria, New York, New York
The 19th Annual Bio CEO & Investor Conference in New York City brings together a lineup of biotech companies, public and private equity investors, and members of the sell-side investment community for a two-day event that provides insight into the current investment landscape and opportunities in life sciences. In addition to plenary sessions and panel discussions, the conference features presentations by over 175 leading biotech and pharmaceutical companies, as well as a number of non-profit and venture philanthropy organizations. For more information visit www.bio.org
22nd Century (XXII)
22nd Century (NYSE: XXII) is a plant biotech company providing technology that allows for the level of nicotine and other nicotinic alkaloids in tobacco plants and the level of cannabinoids in cannabis plants to be decreased or increased through genetic engineering and plant breeding. The company develops smoking cessation products and modified risk tobacco products for smokers who are unable or unwilling to quit smoking and who may be interested in cigarettes, which reduce exposure to nicotine or to certain tobacco smoke toxins and/or pose a lower health risk than conventional cigarettes. For more information, visit the company's website at www.xxiicentury.com.
AcelRx Pharmaceuticals (ACRX)
AcelRx Pharmaceuticals (NASDAQ: ACRX) is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. An NDA for DSUVIA (sufentanil sublingual tablet, 30 mcg) was recently submitted to the FDA for review. The company's follow on product, ZALVISO® (sufentanil sublingual tablet system), designed for the management of moderate-to-severe acute pain in adult patients in the hospital setting, is currently enrolling patients in a phase 3 clinical trial, IAP312. For more information, visit the company's website at www.acelrx.com.
Actinium Pharmaceuticals (ATNM)
Actinium Pharmaceuticals (NYSE: ATNM) is a biopharmaceutical company developing innovative targeted payload immunotherapies for the treatment of advanced cancers. The company's radioimmunotherapy product candidates are based on the combination of the cancer targeting precision of monoclonal antibodies (mAb) that seek out specific types of cells combined with the cytotoxic killing power of radioisotopes that unleash their energy once they have reached their target. For more information, visit the company's website at www.actiniumpharma.com.
Aeterna Zentaris (AEZS)
Aeterna Zentaris (NASDAQ: AEZS) is a specialty biopharmaceutical company engaged in developing and commercializing Zoptrex™, a novel cytotoxic compound. To ensure development, registration and launch of the product, the company intends to license out certain commercial rights to Zoptrex™. The company also actively seeks opportunities to in-license and acquire products for U.S. commercialization. For more information, visit the company's website at www.aezsinc.com.
Agile Therapeutics (AGRX)
Agile Therapeutics (NASDAQ: AGRX) is a progressive women's healthcare company dedicated to fulfilling the unmet health needs of today's women. The company's current product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Its lead product candidate, Twirla®, (ethinyl estradiol and levonorgestrel transdermal system), also known as AG200-15, is a once-weekly prescription contraceptive patch that recently completed Phase 3 trials. Twirla is based on the company's proprietary transdermal patch technology, called Skinfusion®, which is designed to provide advantages over currently available patches and is intended to optimize patch adhesion and patient wearability. For more information, visit the company's website at www.agiletherapeutics.com.
Akari Therapeutics (AKTX)
Akari Therapeutics (NASDAQ: AKTX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement C5 and Leukotriene B4 (LTB4), including paroxysmal nocturnal hemoglobinuria ("PNH"), atypical Hemolytic Uremic Syndrome ("aHUS"), and Guillain Barré syndrome ("GBS"). Exploiting the power of nature, Akari is also developing other tick derived proteins and expects to bring additional compounds to clinical trials over the next several years, as well as engineered forms that allow for potential oral absorption. For more information, visit the company's website at www.akaritx.com.
Akebia Therapeutics (AKBA)
Akebia Therapeutics (NASDAQ: AKBA) is a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor biology. Akebia's lead product candidate, vadadustat, is an oral therapy in development for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients. Akebia's global phase 3 program for vadadustat, which includes the PRO2TECT studies for non-dialysis patients with anemia secondary to chronic kidney disease and the INNO2VATE studies for dialysis-dependent patients, is currently ongoing. For more information, visit the company's website at www.akebia.com.
Albireo Pharma (ALBO)
Albireo Pharma (NASDAQ: ALBO) is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. The company's clinical pipeline includes two phase 2 product candidates and one phase 3 product candidate. Albireo was spun out from AstraZeneca in 2008. Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary is located in Gothenburg, Sweden. For more information, visit the company's website at www.albireopharma.com.
Alcobra (NASDAQ: ADHD) is an emerging pharmaceutical company primarily focused on the development and commercialization of its proprietary drug, METADOXINE EXTENDED RELEASE (MDX), to treat cognitive disorders including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome (FXS). Alcobra's objective is to develop and commercialize proprietary pharmaceutical products for treatment of central nervous system disorders, and cognitive dysfunctions in particular. For more information, visit the company's website at www.alcobra-pharma.com.
AmpliPhi Bio (APHB)
AmpliPhi Bio (NYSE: APHB) focuses on the discovery, development and commercialization of various bacteriophage therapeutics. Its lead product candidate, AB-SA01, is in phase I clinical trial for the treatment of staphylococcus aureus (S. aureus) infections, including methicillin-resistant S. aureus (MRSA). Other products under development include AB-PA01 for the treatment of pseudomonas aeruginosa lung infections in cystic fibrosis patients; and AB-CD01 for the treatment of clostridium difficile infections. For more information, visit the company's website at www.ampliphibio.com.
Anavex Life Sciences (AVXL)
Anavex Life Sciences (NASDAQ: AVXL) is a biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer. Anavex's lead drug candidate, ANAVEX 2-73, recently completed successfully a Phase 2a clinical trial for Alzheimer's disease. The Michael J. Fox Foundation for Parkinson's Research has awarded Anavex a research grant to develop ANAVEX 2-73 for the treatment of Parkinson's disease to fully fund a preclinical study, which could justify moving ANAVEX 2-73 into a Parkinson's disease clinical trial. For more information, visit the company's website at www.anavex.com.
Aradigm (NASDAQ: ARDM) is a specialty pharmaceutical company focused on the development and commercialization of drugs for the prevention and treatment of severe respiratory diseases. Aradigm is completing phase 3 development of Pulmaquin® (an investigational proprietary formulation of ciprofloxacin for inhalation) for the treatment of non-cystic fibrosis bronchiectasis. Aradigm's inhaled ciprofloxacin formulations including Pulmaquin are also product candidates for treatment of patients with cystic fibrosis and non-tuberculous mycobacteria, and for the prevention and treatment of high threat and bioterrorism infections. The company has a pipeline of programs to prevent diseases in tobacco smokers through smoking cessation and a diagnostic program to detect aspirations of gastrointestinal fluid into the respiratory tract. For more information, visit the company's website at www.aradigm.com.
Arch Therapeutics (ARTH)
Arch Therapeutics (OTCQB: ARTH) is a biotech company developing an innovative, elegant and superior approach to the rapid cessation of bleeding (hemostasis) and control of fluid leakage (sealant) during surgery and trauma care. The underlying technology, exclusively licensed from a leading university, supports an innovative platform of smart materials that fulfill the criteria as a solution for a specialized field we call, "stasis and barrier applications." For more information, visit the company's website at www.archtherapeutics.com.
Arena Pharmaceuticals (ARNA)
Arena Pharmaceuticals (NASDAQ: ARNA) is a biopharmaceutical company focused on developing novel, small molecule drugs across a range of therapeutic areas. The company currently has three primary proprietary investigational clinical programs: APD334 in phase 2 evaluation for ulcerative colitis; APD371 entering phase 2 evaluation for the treatment of pain associated with Crohn's disease; and APD811 in phase 2 evaluation for pulmonary arterial hypertension (PAH). Additionally, Arena has collaborations with multiple pharmaceutical companies including Eisai Co. Ltd., and Eisai Inc., Axovant Sciences Ltd., and Boehringer Ingelheim International GmbH. For more information, visit the company's website at www.arenapharm.com.
Argos Therapeutics (ARGS)
Argos Therapeutics (NASDAQ: ARGS) is an immuno-oncology company that utilizes its Arcelis® technology platform to develop and commercialize customized immunotherapies for the treatment of cancer and infectious diseases. The company's most advanced product candidate, rocapuldencel-T, is being evaluated in the pivotal ADAPT phase 3 clinical trial for the treatment of mRCC. In addition, rocapuldencel-T is being studied in phase 2 investigator-initiated clinical trials as neoadjuvant therapy for RCC and for the treatment of NSCLC. Argos is also developing a separate Arcelis®-based product candidate, AGS-004, for the treatment of human immunodeficiency virus (HIV), which is currently being evaluated in an investigator-initiated clinical trial aimed at HIV eradication in adult patients. For more information, visit the company's website at www.argostherapeutics.com.
AVEO Pharmaceuticals (AVEO)
AVEO Pharmaceuticals (NASDAQ: AVEO) is a biopharmaceutical company advancing a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need. The company is focused on developing and commercializing its lead candidate tivozanib in North America as a treatment for Renal Cell Carcinoma and other cancers. AVEO is leveraging multiple partnerships to develop and commercialize tivozanib in non-oncologic indications worldwide and oncology indications outside of North America, as well as to progress its pipeline of novel therapeutic candidates in cancer and cachexia (wasting syndrome). For more information, visit the company's website at www.aveooncology.com.
Axsome Therapeutics (AXSM)
Axsome Therapeutics (NASDAQ: AXSM) is a fully integrated biopharmaceutical business that develops therapies to treat and manage central nervous system (CNS) disorders. Axsome's product candidate portfolio includes two late-stage candidates, AXS-05 and AXS-02. AXS-05 is currently in a phase 3 trial in treatment resistant depression, and a phase 2/3 trial in agitation in patients with Alzheimer's disease (AD) is planned. AXS-02 is currently in phase 3 trials in complex regional pain syndrome and knee osteoarthritis (OA) associated with bone marrow lesions with an additional phase 3 trial planned in chronic low back pain associated with modic changes. AXS-05 and AXS-02 are investigational drug products not approved by the FDA. For more information, visit the company's website at www.axsome.com.
Bellerophon Therapeutics (BLPH)
Bellerophon Therapeutics (NASDAQ: BLPH) is a clinical-stage biotherapeutics company developing innovative drug/device therapies to address unmet medical needs in the treatment of cardiopulmonary diseases. Under the company's INOpulse program, there are currently three product candidates in development. The first candidate is for the treatment of pulmonary arterial hypertension (PAH), for which the company has commenced phase 3 clinical trials in 2016. The second is for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD) and the third candidate is for the treatment of pulmonary hypertension associated with Idiopathic Pulmonary Fibrosis (PH-IPF); both of these products are in phase 2 development. For more information, visit the company's website at www.bellerophon.com.
BioLineRx (NASDAQ: BLRX) is a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates. The company in-licenses novel compounds, primarily from academic institutions and biotech companies based in Israel, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization. BioLineRx's leading therapeutic candidates are: BL-8040, a cancer therapy platform which has successfully completed a phase 2a study; and BL-7010 for celiac disease and gluten sensitivity, which has successfully completed a phase 1/2 study. BioLineRx also has multiple collaboration agreements with other companies. For more information, visit the company's website at www.biolinerx.com.
Bio-Path Holdings (BPTH)
Bio-Path Holdings (NASDAQ: BPTH) is a biotech company focused on developing therapeutic products utilizing DNAbilize™, its proprietary liposomal delivery and antisense technology, to systemically distribute nucleic acid drugs throughout the human body with a simple intravenous transfusion. Bio-Path's lead product candidate, BP1001 (Liposomal Grb2 antisense), is in a phase 2 study for blood cancers and in preclinical studies for solid tumors. Bio-Path's second drug candidate, also a liposomal antisense drug, is ready for the clinic where it will be evaluated in lymphoma and solid tumors. For more information, visit the company's website at www.biopathholdings.com.
BioTime (NYSE: BTX) is a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases. The foundation of BioTime's core therapeutic technology platform is pluripotent cells, which are capable of becoming any of the cell types in the human body. Pluripotent cells have potential application in many areas of medicine with large unmet patient needs, including various age-related degenerative diseases and degenerative conditions for which there presently are no cures. Unlike pharmaceuticals that require a molecular target, therapeutic strategies based on the use of pluripotent cells are generally aimed at regenerating or replacing affected cells and tissues, and therefore may have broader applicability than pharmaceutical products. For more information, visit the company's website at www.biotimeinc.com.
BrainStorm Cell Therapeutics (BCLI)
BrainStorm Cell Therapeutics (NASDAQ: BCLI) is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The company holds the rights to develop and commercialize its NurOwn® technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn® has been administered to approximately 75 patients with ALS in clinical trials conducted in the United States and Israel. In a randomized, double-blind, placebo-controlled clinical trial conducted in the U.S., a clinically meaningful benefit was demonstrated by higher response to NurOwn® compared with placebo. For more information, visit the company's website at www.brainstorm-cell.com.
Caladrius Biosciences (CLBS)
Caladrius Biosciences (NASDAQ: CLBS) is advancing a proprietary platform technology for immunomodulation by pioneering the use of T regulatory cells as an innovative therapy for recent onset Type 1 diabetes. The company's product candidate, CLBS03, is the subject of an ongoing phase 2 clinical trial in collaboration with Sanford Research, and has been granted Orphan Drug and Fast Track designation by the FDA and Advanced Therapeutic Medicinal Product classification by the European Medicines Agency. The company's PCT subsidiary is a development and manufacturing partner to the cell therapy industry. For more information, visit the company's website at www.caladrius.com.
Calithera Biosciences (CALA)
Calithera Biosciences (NASDAQ: CALA) is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Calithera's lead product candidate, CB-839, is currently being evaluated in phase 1/2 clinical trials in combination with standard of care agents. CB-1158 is a first-in-class immuno-oncology metabolic checkpoint inhibitor targeting arginase, a critical immunosuppressive enzyme responsible for T-cell suppression by myeloid-derived suppressor cells (MDSCs). Arginase depletes arginine, a nutrient that is critical for the activation, growth and survival of the body's cancer-fighting immune cells, known as cytotoxic T-cells. CB-1158 is currently in a phase 1 clinical trial. For more information, visit the company's website at www.calithera.com.
Capnia (NASDAQ: CAPN) is a provider and developer of innovative healthcare products to be used for the screening, detection and treatment of medical conditions. The company's flagship products are based on its proprietary technologies, which utilize precision metering of gas flow. Capnia currently markets Serenz® Allergy Relief in the UK. The CoSense® ETCO Monitor measures ETCO, which can be used to detect hemolysis and the Infant Solutions product line, including innovative pulmonary resuscitation devices for neonates and infants, are marketed globally. Capnia is also clinically evaluating its nasal, non-inhaled CO2 technology to treat trigeminally-mediated pain conditions such as cluster headache and trigeminal neuralgia. For more information, visit the company's website at www.capnia.com.
Cellectar Biosciences (CLRB)
Cellectar Biosciences (NASDAQ: CLRB) is developing phospholipid drug conjugates (PDCs) designed to provide cancer targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells. Cellectar's PDC platform is based on the company's proprietary phospholipid ether analogs. The company's lead therapeutic PDC, CLR 131, is currently being evaluated under an orphan drug designated phase I clinical study in patients with relapsed or refractory multiple myeloma. In addition, the company plans to initiate a phase II clinical study to assess efficacy in a range of B-cell malignancies in the first quarter of 2017. The company is also developing PDCs for targeted delivery of chemotherapeutics such as CLR 1603-PTX, a preclinical stage product candidate, and plans to expand its PDC chemotherapeutic pipeline through both in-house and collaborative R&D efforts. For more information, visit the company's website at www.cellectar.com.
Cellular Biomedicine Group (CBMG)
Cellular Biomedicine Group (NASDAQ: CBMG) develops proprietary cell therapies for the treatment of cancer and degenerative diseases. The company's immuno-oncology and stem cell projects are the result of research and development by CBMG's scientists and clinicians from both China and the United States. Its GMP facilities in China, consisting of 12 independent cell production lines, are designed and managed according to both China and U.S. GMP standards. For more information, visit the company's website at www.cellbiomedgroup.com.
Chembio Diagnostics (CEMI)
Chembio Diagnostics (NASDAQ: CEMI) develops, manufactures, licenses and markets proprietary rapid diagnostic tests. The company markets each of its assays in the U.S. and internationally, both directly and through third-party distributors. Chembio's SURE CHECK®HIV 1/2 Assay previously has been exclusively sold in the U.S. as Clearview® Complete HIV 1/2 Assay. Additionally, the company's patented point-of-care (POC) test platform technology, the Dual Path Platform, has provided a significant pipeline of business opportunities for the development and manufacture of new products. For more information, visit the company's website at www.chembio.com.
Citius Pharmaceuticals (CTXR)
Citius Pharmaceuticals (OTC: CTXR) is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products. The company has a focus on anti-infectives, cancer care, and unique prescription products using innovative, patented, or proprietary formulations of previously approved active pharmaceutical ingredients. By using previously approved drugs with substantial safety and efficacy data, the company seeks to reduce the risks associated with pharmaceutical product development and regulatory requirements, and focuses on developing products that have intellectual property protection and competitive advantages to existing therapeutic approaches. For more information, visit the company's website at www.citiuspharma.com.
Conatus Pharmaceuticals (CNAT)
Conatus Pharmaceuticals (NASDAQ: CNAT) is a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease. Conatus is currently developing its lead compound, emricasan, for the treatment of patients with chronic liver disease. Emricasan is designed to reduce the activity of enzymes that mediate inflammation and apoptosis. The company believes that by reducing the activity of these enzymes, emricasan has the potential to interrupt the disease progression across the spectrum of liver disease. For more information, visit the company's website at www.conatuspharma.com.
ContraVir Pharmaceuticals (CTRV)
ContraVir Pharmaceuticals (NASDAQ: CTRV) is focused on the development and commercialization of targeted antiviral therapies with a specific focus on developing a potentially curative therapy for hepatitis B virus (HBV). The company is developing two novel anti-HBV compounds with complementary mechanisms of action: Tenofovir Exalidex™ (formerly CMX157), a highly potent analog of the successful antiviral drug tenofovir; and Valnivudine ™ (formerly FV-100), an orally available nucleoside analogue prodrug for the treatment of herpes zoster, or shingles, in a phase 3 clinical trial. In addition to direct antiviral activity, Valnivudine™ has demonstrated the potential to reduce the incidence of debilitating shingles-associated pain known as post-herpetic neuralgia in a phase 2 clinical study. For more information, visit the company's website at www.contravir.com.
Corium International (CORI)
Corium International (NASDAQ: CORI) is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage the company's experience with advanced transdermal and transmucosal delivery systems. Corium has multiple proprietary programs in preclinical and clinical development, focusing primarily on the treatment of neurological disorders, with lead programs in Alzheimer's disease. Additionally, the company has two proprietary transdermal platforms. Its late-stage pipeline includes a contraceptive patch co-developed with Agile Therapeutics that has recently completed all subject visits for its phase 3 trial, and additional transdermal products that are being developed with other partners. For more information, visit the company's website at www.coriumgroup.com.
CTI BioPharma (CTIC)
CTI BioPharma (NASDAQ: CTIC) is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers. CTI BioPharma has a commercial presence in Europe with respect to PIXUVRI® and a late-stage development pipeline, including pacritinib for the treatment of patients with myelofibrosis. The company is headquartered in Seattle, Washington, with offices in London and Milan under the name CTI Life Sciences Limited. For more information, visit the company's website at www.ctibiopharma.com.
Cyclacel Pharmaceuticals (CYCC)
Cyclacel Pharmaceuticals (NASDAQ: CYCC) is a clinical-stage biopharmaceutical company using cell cycle control and DNA damage response biology to develop innovative, targeted medicines for cancer and other proliferative diseases. The SEAMLESS randomized phase 3 trial of sapacitabine as front-line treatment for AML in the elderly under an SPA with FDA has completed enrollment and follow-up. Cyclacel's pipeline includes an oral combination of seliciclib and sapacitabine in phase 1 in advanced solid tumors, including patients with BRCA mutations; sapacitabine in phase 2 in MDS; and CYC065 in phase 1 in solid tumors with potential utility based on preclinical data also in hematological malignancies. Cyclacel's strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a pipeline of novel drug candidates. For more information, visit the company's website at www.cyclacel.com.
CymaBay Therapeutics (CBAY)
CymaBay Therapeutics (NASDAQ: CBAY) is focused on developing therapies to treat metabolic diseases with high unmet medical need, including serious rare and orphan disorders. A phase 2 study of the company's seladelpar candidate established that it has an anti-atherogenic lipid profile. Arhalofenate, CymaBay's other product candidate, is a potential Urate-Lowering Anti-Flare Therapy that has completed five phase 2 studies in subjects with gout. Arhalofenate has been found to reduce painful flares in joints while at the same time lowering serum uric acid by promoting excretion of uric acid by the kidney. Arhalofenate has been licensed in the U.S. to Kowa Pharmaceuticals America, Inc. CymaBay retains full development and commercialization rights for arhalofenate outside the U.S. For more information, visit the company's website at www.cymabay.com.
Cytosorbents (NASDAQ: CTSO) is a critical care-focused immunotherapy company that engages in the research, development and commercialization of medical devices with its platform blood purification technology incorporating a proprietary adsorbent polymer technology. Its principal product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; for the adjunctive therapy in other critical care applications; the prevention of post-operative complications of cardiopulmonary bypass surgery and damage to organs donated by brain-dead donors prior to organ harvest; and the treatment of chronic kidney failure. For more information, visit the company's website at www.cytosorbents.com.
ImmunoVaccine (OTC: IMMVF) is a clinical stage biopharmaceutical company that develops products based on its proprietary vaccine enhancement platform with a primary focus on T cell activating therapies for cancer. The company's DepoVax vaccine-adjuvanting platform is a patented vaccine delivery formulation that provides controlled and prolonged exposure of antigens adjuvant to the immune system. Its product pipeline includes DPX-Survivac, a therapeutic cancer vaccine; DPX-0907, a therapeutic cancer vaccine that has completed phase I/Ib clinical trials for the treatment of breast, ovarian, and prostate cancer; and DPX-RSV, which is in phase I/Ib clinical trials for the treatment of respiratory diseases. For more information, visit the company's website at www.imvaccine.com.
Invitae (NYSE: NVTA) is a genetic information company that focuses on bringing comprehensive genetic information into mainstream medical practice to enhance the quality of healthcare. It processes DNA-containing samples, analyzes information about patient-specific genetic variation, and generates test reports for clinicians and their patients using an integrated portfolio of laboratory processes, software tools, and informatics' capabilities. The company provides a diagnostic service comprising hundreds of genes for various genetic disorders associated with oncology, cardiology, neurology, pediatrics and other rare disease areas. For more information, visit the company's website at www.invitae.com.
InVivo Therapeutics (NVIV)
InVivo Therapeutics (NASDAQ: NVIV) is a research and clinical-stage biomaterials and biotechnology company focusing on developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold for acute SCI; and Bioengineered Neural Trails™ injection program for the treatment of chronic SCI. The company was founded in 2005 and is based in Cambridge, Massachusetts. For more information, visit the company's website at www.invivotherapeutics.com.
ITUS (NASDAQ: ITUS) funds, develops, acquires and licenses emerging technologies in the areas of biotechnology. Through its subsidiary, Anixa Diagnostics Corporation, ITUS is developing a platform called Cchek, a series of non-invasive, blood tests for the early detection of solid tumor based cancers. It has a collaborative research agreement with The Wistar Institute for the development and validation of Cchek. ITUS was founded in 1982 and is based in Los Angeles, California. For more information, visit the company's website at www.ITUScorp.com.
KaloBios Pharmaceuticals (KBIO)
KaloBios Pharmaceuticals (OTC: KBIO) develops monoclonal antibody therapeutics for the treatment of cancer in the United States. Its lead product candidate is benznidazole for the treatment of Chagas disease. The company is also developing proprietary monoclonal antibodies, including lenzilumab, which is in phase I clinical trial in patients with chronic myelomonocytic leukemia; and ifabotuzumab that has completed phase I/II clinical trial in multiple hematologic malignancies, as well as evaluating further studies of ifabotuzumab in rare solid tumors, such as glioblastoma, other brain cancers in children, and rare hematologic cancer indications. For more information, visit the company's website at www.kalobios.com.
KemPharm (NASDAQ: KMPH) is a clinical-stage specialty pharmaceutical company that discovers and develops new proprietary prodrugs in the United States. Its advanced product candidate is KP201/APAP, which consists of KP201 prodrug of hydrocodone formulated in combination with acetaminophen (APAP). The company is also developing KP201/APAP as an immediate release (IR) product candidate for the treatment of acute pain, as well as engages in designing KP201/APAP with abuse-deterrent properties to address the epidemic of opioid abuse. The company is also involved in developing KP201/IR (APAP-free), an IR formulation of KP201 without APAP for the short-term management of acute pain. For more information, visit the company's website at www.kempharm.com.
MabVax Therapeutics (MBVX)
MabVax Therapeutics (NASDAQ: MBVX) is a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer. The company has discovered a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been vaccinated against targeted cancers with the company's proprietary vaccines. MabVax's HuMab-5B1 antibody is fully human and was discovered from the immune response of cancer patients vaccinated with an antigen-specific vaccine during a phase I trial at Memorial Sloan Kettering Cancer Center, or MSK. For more information, visit the company's website at www.mabvax.com.
Madrigal Pharmaceuticals (MDGL)
Madrigal Pharmaceuticals (NASDAQ: MDGL) is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of therapies for the treatment of cardiovascular, metabolic and liver diseases. The company's lead candidate is MGL-3196, which has completed phase I single and multiple dose trials, an orally administered and small-molecule liver-directed selective thyroid hormone receptor-beta agonist for use in the treatment of nonalcoholic steatohepatitis (NASH), and heterozygous and homozygous familial hypercholesterolemia (FH) to lower LDL cholesterol, triglyceride levels, and Lp(a). For more information, visit the company's website at www.madrigalpharma.com.
Mast Therapeutics (MSTX)
Mast Therapeutics (NYSE: MSTX) is a clinical-stage biopharmaceutical company that develops therapies for serious or life-threatening diseases with significant unmet needs. The company's lead product candidate is MST-188 (vepoloxamer), an injection used for the treatment of sickle cell disease, arterial disease and heart failure. It also develops AIR001, a sodium nitrite solution for intermittent inhalation via nebulizer, as well as for the treatment of heart failure with preserved ejection fraction. For more information, visit the company's website at www.masttherapeutics.com.
Mateon Therapeutics (MATN)
Mateon Therapeutics (OTC: MATN) is a biopharmaceutical company focused on the development of vascular disrupting agents for the treatment of cancer in the United States. Its principal clinical stage product includes fosbretabulin tromethamine, a reversible tubulin binding agent which has completed phase II clinical trial for treating recurrent ovarian cancer; and in phase II clinical trial for treating gastrointestinal neuroendocrine tumors. The company also develops OXi4503 that is in phase I/II clinical trial stage for treating patients with relapsed or refractory acute myelogenous leukemia or myelodysplastic syndromes. For more information, visit the company's website at www.mateon.com.
MetaStat (OTC: MTST) is a molecular diagnostic company focused on the development and commercialization of novel diagnostic tests that provide oncologists with clinically actionable information to optimize cancer treatment. The company is developing two driver-based diagnostic product lines, such as MetaSite Breast test, a tissue-based immunohistochemistry assay applicable for early stage invasive breast cancer patients; and MenaCalc platform, a tissue-based quantitative immunofluorescence assay that applies to various epithelial-based cancers, including breast, lung, colorectal and prostate. For more information, visit the company website at www.metastat.com.
Mount TAM Biotechnologies (MNTM)
Mount TAM Biotechnologies (OTC: MNTM) is a specialty biopharmaceutical company focused on the discovery and development of novel mTOR modulators to address serious unmet need across a range of therapeutic areas. Combining its research collaboration with the world-renowned Buck Institute for Research on Aging, the company's proprietary discovery platform and lead compound targeting systemic lupus erythematosus (SLE), TAM-01, Mount Tam brings a unique focus and value proposition to the biotechnology space. For more information, visit the company's website at www.mounttambiotech.com.